Compare TTRX & CD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTRX | CD |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.8M | 323.4M |
| IPO Year | 2025 | 2014 |
| Metric | TTRX | CD |
|---|---|---|
| Price | $11.11 | $7.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 145.0K | ★ 250.3K |
| Earning Date | 11-25-2026 | 08-31-2023 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,867,068.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $900.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.93 |
| 52 Week Low | $2.57 | $2.10 |
| 52 Week High | $16.45 | $14.10 |
| Indicator | TTRX | CD |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 56.62 |
| Support Level | $9.02 | $3.53 |
| Resistance Level | $14.39 | $8.89 |
| Average True Range (ATR) | 1.25 | 1.63 |
| MACD | -0.41 | 0.26 |
| Stochastic Oscillator | 1.09 | 36.72 |
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.